Grand Pharmaceutical Group Limited Annual Report 2025 – Key Investor Insights

Summary of Key Financial Results

• Revenue: Grand Pharma reported a record revenue of HK\$12.28 billion, up 5.5% from HK\$11.64 billion in 2024.
• Profit for the Year: Net profit sharply declined to HK\$1.24 billion from HK\$2.47 billion in 2024, a decrease of nearly 50%, which is significant and likely to affect share price.
• Profit Before Tax: HK\$1.49 billion, down from HK\$2.85 billion in 2024.
• Earnings Per Share: Basic and diluted EPS fell to HK\$0.3544 from HK\$0.7049.
• Final Dividend: Proposed final dividend of HK\$591.8 million at 16.9 HK cents per share, lower than last year’s dividend of HK\$910.5 million (26 HK cents per share). No interim dividend declared.
• Net Assets: Increased to HK\$17.18 billion from HK\$16.53 billion.
• Gearing Ratio: Net debt to equity ratio rose to 21.1% from 18.8%.
• Gross Profit: HK\$6.78 billion, nearly flat compared to 2024 (HK\$6.74 billion).
• Cash and Bank Balances: HK\$1.14 billion, down from HK\$1.34 billion.
• Current Ratio: Fell to 1.14 from 1.22, indicating tighter liquidity.
• Staff Count: Increased to 12,614 (from 11,987).

Major Strategic and Business Developments

• Innovation-Driven Growth: The company continues to focus on radiopharmaceuticals, ophthalmology, and critical care, expediting clinical trials and launches for priority projects. It is strengthening First-in-Class (FIC) and Best-in-Class (BIC) innovations.
• Global Expansion: Grand Pharma is advancing its “dual filing in China and the U.S.” strategy, targeting overseas markets with self-developed drugs like GPN01530 and STC3141. It is also refining its overseas commercialization network and leveraging YiGanTai® globalization.
• ESG and Recognition: In 2025, the company was ranked among the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness” and received awards for investor relations and Stock Connect performance.
• M&A and Integration: The group’s continued success in mergers, acquisitions, and integration of raw materials and preparations improved the industrial chain structure and diversified business, enhancing overall competitive advantages.
• R&D and Milestones: In 2025, the company achieved 65 significant milestones, including 32 innovative products.

Risks and Uncertainties (Price Sensitive)

• Earnings Decline: The substantial drop in net profit and dividend payout is a major price-sensitive issue. Investors should monitor management’s explanations and future guidance.
• Foreign Exchange Risk: Most transactions are settled in RMB. No hedging activities for foreign currency risks were carried out in 2025. Significant exchange rate fluctuations may impact financials.
• Interest Rate Risk: The Group is exposed to interest rate fluctuations, especially on variable-rate borrowings. A 100 basis point change could impact profit after tax by HK\$735,000.
• Liquidity Risk: The current ratio has weakened and cash balances have dropped. Management states the financial position is healthy, but the lower liquidity may be a concern for investors.
• Investment Risk: The group continues to balance risks and returns across its portfolio, with regular updates to the Board and detailed risk assessment processes.
• Economic Environment: The Group’s operations are heavily dependent on Mainland China and Hong Kong. Any negative economic developments or regional downturns could adversely affect results.
• Equity Price Risk: The Group is exposed to equity price risk from investments in both listed and unquoted equity instruments. A 5% change in prices could impact profit and other comprehensive income.
• Impairment Provisions: HK\$38.7 million in provision for expected credit losses, and no impairment in goodwill this year compared to HK\$49 million last year.

Corporate Governance and Shareholder Rights

• Board Structure: The Board is actively involved in strategy, risk management, and monitoring performance. Four executive directors and four independent non-executive directors.
• Risk Management: No major issues found in annual review; risk management and internal controls considered effective and adequate.
• Shareholder Communication: Multiple channels for communication, including general meetings, annual reports, and direct contact with the company secretary.
• Dividend Policy: Dividends are subject to financial performance, reserves, liquidity, expansion plans, and market conditions. No assurance on future dividend payments.
• Public Float: Maintained sufficient public float as required under the Listing Rules.
• Share Capital: No share option scheme adopted or outstanding options as at year-end. No share buy-backs or treasury shares movements. No pre-emptive rights.
• Major Shareholders: Outwit Investments Ltd., Grand (Hongkong) International Investments Holdings Ltd., China Grand Enterprises Incorporation, and Mr. Hu Kaijun together hold over 53% of shares. CDH Giant Health I Ltd. and related entities hold 8.62%.

Related Party Transactions

• Connected Transactions: Significant ongoing transactions with Huadong Medicine, Baoding Jiufu, and Sirtex Medical. All transactions reviewed by independent directors and auditors, confirmed to be on normal commercial terms and within announced cap amounts.
• No Material Breach: No material breach of laws or non-compliance reported during the year.

Operational Highlights

• Employee Remuneration: Staff costs rose to HK\$2.2 billion. The company employs 12,614 staff in HK and PRC.
• R&D Expenditure: Research and development expenditure remains high at HK\$502.9 million.
• Marketing and Promotion: Expenses totaled HK\$922.4 million, reflecting continued investment in brand and product launches.
• Capital Expenditure: Details of movement in property, plant, equipment, and bank borrowings disclosed in notes to financial statements.

Accounting and Audit

• Audit Opinion: Independent auditors HLB Hodgson Impey Cheng Limited gave a clean opinion – financial statements present a true and fair view, prepared in accordance with HKFRS and HK Companies Ordinance.
• Key Audit Matters: Focused on recoverability of trade/other receivables and impairment assessment on interests in associates, both considered significant due to material balances and management judgement.

Conclusion – Potential Share Price Impacts

• Negative: The sharp fall in net profit, lower dividend, and declining liquidity are likely to be seen as negative by investors and could pressure the share price.
• Positive: Ongoing innovation, global expansion, strong net asset value, and industry recognition may offset some negative sentiment, depending on market outlook and management’s guidance.
• Risks: Investors should watch for further developments in clinical trials, M&A activities, and macroeconomic factors affecting China and HK.

Disclaimer

This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. All financial data is extracted from Grand Pharmaceutical Group Limited’s 2025 Annual Report and is subject to change. Please consult your financial advisor and review company filings before making any investment decisions.

View GRAND PHARMA Historical chart here